Medi Assist sets five-year returns plan and ₹49.3 crore buyback

Medi Assist Healthcare Services Ltd plans to return about 50% of cumulative adjusted free cash flow to shareholders over rolling five-year periods starting in FY 2026–27. The plan permits dividends and buybacks, with an immediate buyback of up to ₹49.3 crore at ₹425 per share, while Medi Assist reported ₹268.3 crore of cash and zero debt in H1FY27.

What is Medi Assist’s shareholder-return framework?

Medi Assist’s framework is to return about half of cumulative adjusted free cash flow over rolling five-year periods beginning in FY 2026–27. The company identifies ordinary dividends, special dividends and share buybacks as the available methods, rather than specifying a fixed form or amount of distribution for each financial year.

The stated capital-allocation sequence puts investment in technology, artificial intelligence and products first, followed by disciplined international and strategic opportunities, maintaining a debt-free balance sheet and returning surplus cash. At FY26, Medi Assist reported ₹260.5 crore of cash and cash equivalents and nil debt; cash and cash equivalents were ₹268.3 crore in H1FY27, with zero debt again reported.

The measure is cumulative, adjusted free cash flow over five years rather than an annual payout ratio. The presentation does not provide the adjustments used to calculate free cash flow or a rupee return target for FY27, so the disclosed policy is a multi-year capital-allocation plan rather than annual dividend guidance.

How does the ₹49.3 crore Medi Assist buyback work?

Medi Assist plans to buy back up to 11,59,199 shares for up to ₹49.3 crore at ₹425 per share. The company says the repurchase will be funded through internal accruals and will use under one-fifth of free cash.

The presentation’s illustrative FY26 calculation shows weighted-average share count declining 1.6%, to 7.12 crore shares from 7.23 crore shares. On the same basis, earnings per share, or EPS, would rise 1.6% to ₹12.34 from ₹12.14; these figures are illustrations using FY26 metrics, not a forecast of earnings.

Medi Assist also illustrates reported return on equity, or ROE, increasing to 11.1% from 10.5%, and return on capital employed, or ROCE, excluding exceptional items increasing to 13.1% from 12.4%. The presentation labels all four buyback effects as FY26 illustrations, including the 0.6-percentage-point ROE and 0.7-percentage-point ROCE changes.

What financial position supports Medi Assist’s return plan?

Medi Assist reported ₹268.3 crore of cash and cash equivalents in H1FY27, compared with ₹260.5 crore at FY26, and reported zero debt in both periods. Net worth increased to ₹886.8 crore from ₹852.4 crore, while contract liability increased to ₹321.7 crore from ₹280.2 crore.

Underlying profit after tax, or PAT, was ₹46.1 crore in H1FY27, compared with ₹30.7 crore in H1FY26. Medi Assist defines underlying PAT as excluding a ₹3.1 crore derivative gain on a call/put option, which it classifies as exceptional.

Operating performance also increased in the first half. Earnings before interest, tax, depreciation and amortisation, or EBITDA, rose 19.0% to ₹97.2 crore in H1FY27 from ₹81.7 crore in H1FY26, while EBITDA margin rose 103 basis points to 20.3% from 19.3%.

The margin comparison follows the consolidation of Paramount Health Services from 1 July 2025. Medi Assist says the acquired revenue initially carried a lower margin, while quarterly EBITDA margin rose to 20.4% in Q2FY27 from 17.1% in Q2FY26 as the integration was completed and 100% of Paramount Health Services claims moved to the MAtrix platform.

How will Medi Assist fund investment alongside shareholder returns?

Medi Assist says technology, artificial intelligence and product investment will be funded from operating cash flows, while it will pursue international and strategic opportunities with discipline. Technology revenue was ₹18.1 crore in H1FY27, up 83.8% year on year, and platform premiums were ₹9,648 crore, up 24.8%.

The technology rollout remains in progress, with three insurers live in H1FY27 and four more scheduled to go live in H2FY27. Seven insurers had contracted for the technology, and Medi Assist reported that more than about 95% of live insurers’ inpatient claims were already running on MAtrix.

The India third-party administrator, or TPA, business remains the largest revenue line. India TPA revenue was ₹437.5 crore in H1FY27, accounting for 91.5% of revenue, compared with ₹19.8 crore, or 4.2%, for platform and health benefits administration, and ₹20.7 crore, or 4.3%, for international operations.

Medi Assist’s group segment generated ₹334.7 crore of H1FY27 revenue, up 13.7% year on year, and managed ₹13,939 crore of premiums, up 21.8%. Retail TPA revenue fell 1.8% to ₹45.5 crore, while platform premiums increased 24.8% to ₹9,648 crore, showing the differing growth patterns between the established TPA business and platform activity.

Conclusion

Medi Assist has formalised a capital-allocation framework that combines internal funding for technology and product development, disciplined growth opportunities, a debt-free balance sheet and shareholder distributions. The up-to-₹49.3 crore buyback is the immediate disclosed return action, while the about-50% objective links future dividends and repurchases to cumulative adjusted free cash flow over rolling five-year periods.

The next disclosed operating milestone is the planned H2FY27 go-live of four additional insurers on the technology platform. Investors can also monitor subsequent disclosures on cash generation, investment requirements and any dividend or buyback actions taken under the FY 2026–27 framework.